Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program

benzinga.com/general/biotech/25/05/45283047/exclusive-adial-pharmaceuticals-secures-fda-end-of-phase-2-meeting-request-to-discuss-upcoming-cl

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek the U.S. Food and Drug Administration (FDA) guidance on the Phase 3 clinical trial for…

This story appeared on benzinga.com, 2025-05-08 12:02:08.
The Entire Business World on a Single Page. Free to Use →